Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of TVAX-008 Injection in Chronic Hepatitis B
ChiCTR2500105590Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2025
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing TVAX-008 injection with Placebo (2 arms). Primary endpoints: HBsAg negative conversion rate at week 49 and HBsAg negative conversion rate at 24 weeks after discontinuation of NAs. Started Jul 2025; status: recruiting.
02
Drugs
TVAX-008
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2500105590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105590.